KR101758409B1 - 방사 면역 접합체 및 그 용도 - Google Patents

방사 면역 접합체 및 그 용도 Download PDF

Info

Publication number
KR101758409B1
KR101758409B1 KR1020127020917A KR20127020917A KR101758409B1 KR 101758409 B1 KR101758409 B1 KR 101758409B1 KR 1020127020917 A KR1020127020917 A KR 1020127020917A KR 20127020917 A KR20127020917 A KR 20127020917A KR 101758409 B1 KR101758409 B1 KR 101758409B1
Authority
KR
South Korea
Prior art keywords
antibody
cells
radioligand
seq
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127020917A
Other languages
English (en)
Korean (ko)
Other versions
KR20130028051A (ko
Inventor
로이 에이치. 라르센
요슈타인 달
오위빈트 에스. 브루란드
Original Assignee
노르딕 나노벡터 에이에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노르딕 나노벡터 에이에스에이 filed Critical 노르딕 나노벡터 에이에스에이
Publication of KR20130028051A publication Critical patent/KR20130028051A/ko
Application granted granted Critical
Publication of KR101758409B1 publication Critical patent/KR101758409B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020127020917A 2010-01-29 2011-01-28 방사 면역 접합체 및 그 용도 Expired - Fee Related KR101758409B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
NO20100143 2010-01-29
US61/299,524 2010-01-29
PCT/EP2011/051231 WO2011092295A2 (en) 2010-01-29 2011-01-28 Novel radioimmunoconjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177018914A Division KR101893720B1 (ko) 2010-01-29 2011-01-28 방사 면역 접합체 및 그 용도

Publications (2)

Publication Number Publication Date
KR20130028051A KR20130028051A (ko) 2013-03-18
KR101758409B1 true KR101758409B1 (ko) 2017-07-14

Family

ID=44319900

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127020917A Expired - Fee Related KR101758409B1 (ko) 2010-01-29 2011-01-28 방사 면역 접합체 및 그 용도
KR1020177018914A Expired - Fee Related KR101893720B1 (ko) 2010-01-29 2011-01-28 방사 면역 접합체 및 그 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177018914A Expired - Fee Related KR101893720B1 (ko) 2010-01-29 2011-01-28 방사 면역 접합체 및 그 용도

Country Status (25)

Country Link
US (2) US8628749B2 (enExample)
EP (2) EP2528627B1 (enExample)
JP (2) JP5646652B2 (enExample)
KR (2) KR101758409B1 (enExample)
CN (2) CN104338154B (enExample)
AU (1) AU2011209441B2 (enExample)
BR (1) BR112012018843B8 (enExample)
CA (1) CA2786655C (enExample)
DK (2) DK2705857T3 (enExample)
ES (2) ES2592402T3 (enExample)
HR (1) HRP20140538T1 (enExample)
IL (2) IL221091A (enExample)
MX (2) MX2012008695A (enExample)
NO (1) NO331080B1 (enExample)
NZ (1) NZ601055A (enExample)
PH (2) PH12012501516A1 (enExample)
PL (1) PL2528627T3 (enExample)
PT (1) PT2528627E (enExample)
RS (1) RS53346B (enExample)
RU (2) RU2560587C9 (enExample)
SG (1) SG182685A1 (enExample)
SI (1) SI2528627T1 (enExample)
UA (1) UA108631C2 (enExample)
WO (1) WO2011092295A2 (enExample)
ZA (1) ZA201205007B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3272364B1 (en) * 2011-12-13 2020-07-29 Nordic Nanovector ASA Chimeric therapeutic anti-cd37 antibodie hh1
RU2014140119A (ru) * 2012-03-30 2016-05-27 Иммьюноджен, Инк. Способы повышения эффективности терапии на основе cd37
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
BR112015030457A2 (pt) * 2013-06-07 2017-08-22 Nordic Nanovector As Método para regular positivamente a expressão de antígeno
AR097161A1 (es) * 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
HK1250646A1 (zh) * 2015-04-07 2019-01-11 Memorial Sloan Kettering Cancer Center 纳米粒子免疫偶联物
GB201600328D0 (en) * 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
SG11201901672RA (en) * 2016-09-16 2019-03-28 Nordic Nanovector Asa Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
CN111372613A (zh) * 2017-11-22 2020-07-03 诺帝克纳诺维科特公司 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3958879A4 (en) * 2019-04-25 2023-05-10 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
MX2023011031A (es) * 2021-03-19 2023-12-14 Heidelberg Pharma Res Gmbh Conjugados de amatoxina y anticuerpo especificos de linfocitos b.
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
US20250333531A1 (en) 2021-10-06 2025-10-30 Nordic Nanovector Asa Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2001080884A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
CA2509103A1 (en) * 2002-12-13 2004-07-01 Mitra Medical Technology Ab Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
JP4874090B2 (ja) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物
JP4912153B2 (ja) * 2003-12-01 2012-04-11 イミューノメディクス、インコーポレイテッド タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
AU2006272555B2 (en) * 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Labelled Compounds and Radiopharmaceuticals, 39(12), 1039-1046, 1997.

Also Published As

Publication number Publication date
EP2705857A2 (en) 2014-03-12
CA2786655C (en) 2016-12-13
RS53346B (sr) 2014-10-31
AU2011209441A1 (en) 2012-07-19
SI2528627T1 (sl) 2014-08-29
US20120301396A1 (en) 2012-11-29
AU2011209441B2 (en) 2016-03-03
WO2011092295A2 (en) 2011-08-04
UA108631C2 (xx) 2015-05-25
EP2528627B1 (en) 2014-03-19
IL237507A0 (en) 2015-04-30
US20140147384A1 (en) 2014-05-29
CN104338154B (zh) 2017-09-22
CN102762230A (zh) 2012-10-31
PH12017501038B1 (en) 2019-02-22
IL221091A0 (en) 2012-09-24
KR101893720B1 (ko) 2018-08-30
NZ601055A (en) 2013-12-20
RU2560587C2 (ru) 2015-08-20
NO331080B1 (no) 2011-09-26
DK2528627T3 (da) 2014-05-12
NO20100143A1 (no) 2011-08-01
DK2705857T3 (en) 2016-08-29
RU2560587C9 (ru) 2015-11-27
BR112012018843A8 (pt) 2017-12-19
BR112012018843A2 (pt) 2017-10-17
ES2592402T3 (es) 2016-11-30
EP2705857B1 (en) 2016-06-22
JP2015057415A (ja) 2015-03-26
KR20130028051A (ko) 2013-03-18
EP2528627A2 (en) 2012-12-05
HK1195736A1 (en) 2014-11-21
ZA201205007B (en) 2013-09-25
MX342539B (es) 2016-10-04
US9358309B2 (en) 2016-06-07
CA2786655A1 (en) 2011-08-04
PH12017501038A1 (en) 2017-12-11
BR112012018843B8 (pt) 2020-12-22
RU2012135430A (ru) 2014-03-10
HK1179157A1 (en) 2013-09-27
PT2528627E (pt) 2014-06-12
PL2528627T3 (pl) 2014-08-29
CN104338154A (zh) 2015-02-11
JP5855209B2 (ja) 2016-02-09
BR112012018843B1 (pt) 2020-09-24
PH12012501516A1 (en) 2024-04-03
KR20170084349A (ko) 2017-07-19
IL221091A (en) 2015-03-31
ES2469140T3 (es) 2014-06-17
CN102762230B (zh) 2014-08-13
HRP20140538T1 (hr) 2014-07-18
WO2011092295A3 (en) 2011-11-24
MX2012008695A (es) 2012-11-23
JP5646652B2 (ja) 2014-12-24
JP2013518086A (ja) 2013-05-20
US8628749B2 (en) 2014-01-14
RU2664475C1 (ru) 2018-08-17
SG182685A1 (en) 2012-08-30
EP2705857A3 (en) 2014-07-30

Similar Documents

Publication Publication Date Title
KR101893720B1 (ko) 방사 면역 접합체 및 그 용도
KR102033819B1 (ko) 상향조절 항원 발현 방법
US20210017295A1 (en) Bispecific binding agents and uses thereof
JP2005503109A (ja) 修飾抗体と使用方法
KR20240035757A (ko) 우로키나제 플라스미노겐 활성화제 수용체-표적화된 방사성 약제
Wojdowska et al. Standardization of Procedures for the Preparation of 177Lu-and 90Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation
Rousseau et al. Radiolabeled antibodies for cancer radioimmunotherapy
HK1195736B (en) Radioimmunoconjugates and their use
HK1179157B (en) Radioimmunoconjugates and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20200625

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20210628

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20220629

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230711

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230711